GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23-01-2020
GSK to widen access to medicines in world’s poorest countries
01-04-2016
360b / Shutterstock.com
GSK has been fined more than £37 million ($53 million) by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat (paroxetine).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, anti-competition, generic, Seroxat, patent, patent infringement, pay-for-delay, GUK, Alpharma, paroxetine, Competition and Markets Authority
